医学
癌症研究
药理学
癌症
抗药性
后天抵抗
表皮生长因子受体抑制剂
威罗菲尼
临床试验
化学
作者
Bridget Kreger,Yanke Liang,Nicole M. Reilly,Meghan E. Spears,William A. Scott,Jeffrey R. Simard,Ping Li,Prasoon Chaturvedi,Roman V. Agafonov,Jacob Stephenson,Joelle Baddour,June A. Hart,Praveen M. Bahadduri,Logan Riegel,Kyle Cole,Riadh Lobbardi,Nicole E. Follmer,Eunju Hurh,Andrew C. Good,Mark E. Fitzgerald
出处
期刊：Cancer Research
[American Association for Cancer Research]
日期：2025-10-28
卷期号：86 (2): 438-452
被引量：2
标识
DOI：10.1158/0008-5472.can-25-1301
摘要
CFT1946 is a clinical stage, orally available, brain-penetrant BRAFV600-mutant protein degrader that overcomes RAF dimer-driven resistance mechanisms to currently approved BRAF inhibitors and represents a promising approach to treating BRAFV600-mutant tumors. See related commentary by Chen and Bollag, p. 289.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
房延彤
Ethan
GingerF
Belikov
Nexus
OsamaKareem
AllRightReserved
8R60d8
火星上的菲鹰
飘逸的书萱
iNk
zhaoyuepu
Starwalker
ZeKaWa
完美的翼
贪玩的秋柔
嘉心糖
arbitmomo
科研狗
皖公网安备34019202002308
